Phase 2 Sickle Cell Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You (or your child) must be older than 6 months of age
- You (or your child) must have been diagnosed with Sickle Cell Disease (a blood condition), of any type
- You (or your child) must need ongoing regular blood transfusions as part of their treatment
- You, your parent, or your guardian must agree to take part by signing a consent form, and children old enough to understand must also agree to join
Who may not be able to join:
- People who have a very rare blood type that would make it too difficult to find enough matching blood units for transfusion
- People who need blood that avoids certain markers (called antigens) due to previous reactions to transfusions, making it too hard to find enough suitable blood units
- People who have developed a reaction (called alloimmunization) specifically against the "D" blood group marker
- People who have developed reactions to certain blood markers where providing specially matched blood could actually expose them to something harmful, going against standard medical practice (confirm with trial site)
- People whose parents, guardians, or who themselves are unlikely to be able to follow the study schedule and requirements, in the opinion of the research team
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stella Chou, MD, Children's Hospital of Philadelphia
Phone: 215-590-0947
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the treatment efficacy by monitoring the rate of Rh alloimmunization; Determine the feasibility of identifying sufficient RH genotype matched units
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.